According to reports from Business Standard, Tejnaksh Healthcare delivered strong profitability growth in the June 2026 quarter, with consolidated net profit rising 8.00% to ₹0.27 crore compared to ₹0.25 crore in the corresponding quarter of the previous year. The company's profit before tax (PBT) increased by 45% to ₹0.42 crore from ₹0.29 crore in Q1 FY2025, demonstrating improved operational efficiency despite recent revenue challenges.
As reported by Business Standard, the company's sales revenue grew modestly by 0.38% to ₹2.65 crore in Q1 FY2026, up from ₹2.64 crore in the same quarter last year. However, recent quarterly data shows net sales declined 20.59% year-on-year to ₹2.55 crore in the March 2026 quarter, indicating some volatility in the company's revenue performance. The revenue growth was relatively modest compared to the significant profit growth, indicating that the company's focus on operational efficiency and cost management contributed to the improved bottom-line performance.
According to the financial data reported by Business Standard, Tejnaksh Healthcare achieved operating profit margin (OPM) of 26.04% in Q1 FY2026, compared to 23.11% in the corresponding quarter of the previous year. The company's profit before depreciation and tax (PBDT) increased by 22% to ₹0.78 crore from ₹0.64 crore in Q1 FY2025, reflecting improved operational performance across key financial metrics. The company operates as Tejnaksh Healthcare Ltd., owning and operating a hospital under the brand name of the Institute of Urology, offering services including pediatric urology, adult urology, andrology, sexual dysfunction, nephrology, dialysis and renal transplant.
